Beverly Hills Private Wealth LLC Sells 735 Shares of QIAGEN N.V. $QGEN

Beverly Hills Private Wealth LLC trimmed its position in shares of QIAGEN N.V. (NYSE:QGEN) by 9.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,724 shares of the company’s stock after selling 735 shares during the period. Beverly Hills Private Wealth LLC’s holdings in QIAGEN were worth $323,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of QGEN. SVB Wealth LLC bought a new position in shares of QIAGEN during the first quarter valued at about $31,000. Farther Finance Advisors LLC raised its stake in shares of QIAGEN by 400.5% during the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock valued at $51,000 after acquiring an additional 849 shares during the last quarter. Hilltop National Bank bought a new position in shares of QIAGEN during the second quarter valued at about $66,000. ANTIPODES PARTNERS Ltd bought a new position in shares of QIAGEN during the first quarter valued at about $94,000. Finally, GAMMA Investing LLC raised its stake in QIAGEN by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock worth $118,000 after buying an additional 1,425 shares in the last quarter. 70.00% of the stock is owned by institutional investors.

QIAGEN Price Performance

Shares of QGEN opened at $48.69 on Tuesday. The stock has a market cap of $10.82 billion, a PE ratio of 28.76, a price-to-earnings-growth ratio of 2.54 and a beta of 0.66. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. QIAGEN N.V. has a fifty-two week low of $37.63 and a fifty-two week high of $51.88. The firm’s 50-day simple moving average is $47.01 and its two-hundred day simple moving average is $45.92.

QIAGEN (NYSE:QGEN) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting analysts’ consensus estimates of $0.60. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The firm had revenue of $533.54 million for the quarter, compared to analysts’ expectations of $523.97 million. During the same quarter in the prior year, the company posted $0.55 earnings per share. The business’s revenue for the quarter was up 7.7% on a year-over-year basis. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Analysts anticipate that QIAGEN N.V. will post 2.26 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. UBS Group increased their price target on shares of QIAGEN from $48.00 to $50.00 and gave the stock a “neutral” rating in a research note on Thursday, August 7th. Wall Street Zen downgraded shares of QIAGEN from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Barclays set a $53.00 price target on shares of QIAGEN and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Bank of America increased their price target on shares of QIAGEN from $50.00 to $53.00 and gave the stock a “buy” rating in a research note on Thursday, June 26th. Finally, Cowen reissued a “hold” rating on shares of QIAGEN in a research note on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $49.69.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.